Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Famotidine  COVID-19 treatment studies for Famotidine  C19 studies: Famotidine  Famotidine   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Symptomatic case 22% Improvement Relative Risk Recovery time 37% Balouch et al. Famotidine for COVID-19 Prophylaxis Is prophylaxis with famotidine beneficial for COVID-19? Retrospective 307 patients in the USA Fewer symptomatic cases (p=0.49) and faster recovery (p=0.32), not stat. sig. Balouch et al., J. Voice, doi:10.1016/j.jvoice.2021.01.007 Favors famotidine Favors control
Role of Famotidine and Other Acid Reflux Medications for SARS-CoV-2: A Pilot Study
Balouch et al., Journal of Voice, doi:10.1016/j.jvoice.2021.01.007
Balouch et al., Role of Famotidine and Other Acid Reflux Medications for SARS-CoV-2: A Pilot Study, Journal of Voice, doi:10.1016/j.jvoice.2021.01.007
Jan 2021   Source   PDF  
  All Studies   Meta
Survey of 307 patients in the USA, showing no significant difference in COVID-19 cases with famotidine use.
risk of symptomatic case, 22.0% lower, RR 0.78, p = 0.49, treatment 18 of 80 (22.5%), control 49 of 227 (21.6%), adjusted per study, odds ratio converted to relative risk, multivariable.
recovery time, 36.9% lower, relative time 0.63, p = 0.32, treatment 80, control 227.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Balouch et al., 20 Jan 2021, retrospective, USA, peer-reviewed, 5 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperFamotidineAll
Abstract: ARTICLE IN PRESS Role of Famotidine and Other Acid Reflux Medications for SARS-CoV-2: A Pilot Study *Bailey Balouch, *Swetha Vontela, *Heather Yeakel, †Ghiath Alnouri, and †,‡Robert T. Sataloff, *yPhiladelphia, and zWynnewood, Pennsylvania Summary: Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the coronavirus-19 disease (COVID-19) pandemic. The H-2 blocker famotidine has been suggested as an FDAapproved drug that could potentially be repurposed for treatment of COVID-19. Famotidine has since been shown to improve patient outcomes and reduce symptom severity in patients acutely ill with COVID-19. Other studies have suggested that proton pump inhibitors (PPIs) might have an association with COVID-19. Objective. The purpose of the present study was to determine whether famotidine or any other antireflux medications have a prophylactic or detrimental effect for SARS-CoV-2 infection when taken regularly for the management of acid reflux. Methods. An anonymous, web-based survey was distributed via email to adult otolaryngology patients to collect demographic data, past medical history, medication history, incidence of symptoms associated with COVID-19, potential exposure to SARS-CoV-2, and results of any PCR or serological testing. Associations between reflux medications and incidence of COVID-19 cases were analyzed. Statistical analysis was performed using SPSS. Chisquare with Fisher’s exact test, Point-Biserial correlation, Kendall’s-tau-b, independent samples t test, and the Mann-Whitney U test were used as appropriate. A binary logistic regression model was fit to determine probability of COVID-19 cases after adjustment for other risk factors. Results. There were 307 patients who responded to the survey. The average age of respondents was 52.63 § 17.03. Famotidine use was not associated with incidence of laboratory-confirmed (P= 0.717) or symptomatically suspected (P= 0.876) COVID-19. No other reflux medications were found to be significant predictors for laboratory-confirmed or suspected COVID-19 (P> 0.05). Younger age (odds ratio [OR] = 1.043, 95% CI: 1.020−1.065, P< 0.001), high risk obesity (OR = 4.005, 95% CI: 1.449−11.069, P= 0.007), and use of a corticosteroid nasal spray (OR = 3.529, 95% CI: 1.352−9.211, P= 0.010) were significant predictors for symptomatically suspected COVID-19 cases. Conclusions. There was no association between incidence of COVID-19 and use of reflux medications, including famotidine at doses used orally to manage reflux and high dose PPIs. Reflux medications did not protect against or increase the risk of COVID-19. Key Words: COVID-19−SARS-CoV-2−Famotidine−Proton pump inhibitor−Intranasal corticosteroid−Age −Obesity.
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop